A preliminary experience of plasma exchange in liver failure

INTRODUCTION: Plasma exchange (PLEX) is one of the experimental modalities of treatment for liver failure. We report our experience of PLEX in patients with acute-(ALF) or acute-on-chronic (ACLF) liver failure. METHODS: Hemodynamically stable adult patients with ALF or ACLF, encephalopathy, model fo...

Full description

Bibliographic Details
Main Authors: Himanshu Dandu, Vivek Kumar, Amit Goel, Dheeraj Khetan, Tulika Chandra, Vipin Raj Bharti
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Asian Journal of Transfusion Science
Subjects:
Online Access:http://www.ajts.org/article.asp?issn=0973-6247;year=2022;volume=16;issue=2;spage=209;epage=213;aulast=Dandu
_version_ 1811200627555958784
author Himanshu Dandu
Vivek Kumar
Amit Goel
Dheeraj Khetan
Tulika Chandra
Vipin Raj Bharti
author_facet Himanshu Dandu
Vivek Kumar
Amit Goel
Dheeraj Khetan
Tulika Chandra
Vipin Raj Bharti
author_sort Himanshu Dandu
collection DOAJ
description INTRODUCTION: Plasma exchange (PLEX) is one of the experimental modalities of treatment for liver failure. We report our experience of PLEX in patients with acute-(ALF) or acute-on-chronic (ACLF) liver failure. METHODS: Hemodynamically stable adult patients with ALF or ACLF, encephalopathy, model for end-stage liver disease (MELD) score ≥ 15, and clinical worsening/no improvement after 72-h of inpatient care were included. PLEX cycles repeated every 48 h, each of 2.5–4.0 h duration with 1–1.5 times of estimated plasma volume, were given. PLEX cycle was repeated till either of the end-points were achieved (i) MELD < 20 for 48 h or reaches below the baseline, whichever is lower, (ii) completed three PLEX cycles, (iii) hemodynamic instability, (iv) or outcome achieved. Outcome of interest was categorized as favorable (discharged in stable condition) or unfavorable (death or discharge in moribund condition). Data are expressed as median (interquartile range). RESULTS: Sixteen patients (age 35 [27–48] years; male 8; ALF 5, ACLF 11; MELD 33 [27–37]; CLIF-SOFA 10 [8.5–12]) were included. Participants received 2 (1-3) cycles of PLEX during 13 (11–25) days of hospitalization. Overall, serum bilirubin, INR, creatinine, MELD, and CLIF-SOFA scores were significantly improved after PLEX. Five patients (5/16, 31%) had complete resolution of HE. Eight patients (50%) had a favorable outcome. Those with favorable outcome had significant improvement in serum bilirubin, INR, and CLIF-SOFA scores as compared to those with unfavorable outcome. CONCLUSION: PLEX may be effective in patients with ALF or ACLF. More data are needed to establish its role in the management of liver failure.
first_indexed 2024-04-12T02:06:46Z
format Article
id doaj.art-44e749226b604d6c86b474fcd38c17b3
institution Directory Open Access Journal
issn 0973-6247
1998-3565
language English
last_indexed 2024-04-12T02:06:46Z
publishDate 2022-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Asian Journal of Transfusion Science
spelling doaj.art-44e749226b604d6c86b474fcd38c17b32022-12-22T03:52:30ZengWolters Kluwer Medknow PublicationsAsian Journal of Transfusion Science0973-62471998-35652022-01-0116220921310.4103/ajts.ajts_115_21A preliminary experience of plasma exchange in liver failureHimanshu DanduVivek KumarAmit GoelDheeraj KhetanTulika ChandraVipin Raj BhartiINTRODUCTION: Plasma exchange (PLEX) is one of the experimental modalities of treatment for liver failure. We report our experience of PLEX in patients with acute-(ALF) or acute-on-chronic (ACLF) liver failure. METHODS: Hemodynamically stable adult patients with ALF or ACLF, encephalopathy, model for end-stage liver disease (MELD) score ≥ 15, and clinical worsening/no improvement after 72-h of inpatient care were included. PLEX cycles repeated every 48 h, each of 2.5–4.0 h duration with 1–1.5 times of estimated plasma volume, were given. PLEX cycle was repeated till either of the end-points were achieved (i) MELD < 20 for 48 h or reaches below the baseline, whichever is lower, (ii) completed three PLEX cycles, (iii) hemodynamic instability, (iv) or outcome achieved. Outcome of interest was categorized as favorable (discharged in stable condition) or unfavorable (death or discharge in moribund condition). Data are expressed as median (interquartile range). RESULTS: Sixteen patients (age 35 [27–48] years; male 8; ALF 5, ACLF 11; MELD 33 [27–37]; CLIF-SOFA 10 [8.5–12]) were included. Participants received 2 (1-3) cycles of PLEX during 13 (11–25) days of hospitalization. Overall, serum bilirubin, INR, creatinine, MELD, and CLIF-SOFA scores were significantly improved after PLEX. Five patients (5/16, 31%) had complete resolution of HE. Eight patients (50%) had a favorable outcome. Those with favorable outcome had significant improvement in serum bilirubin, INR, and CLIF-SOFA scores as compared to those with unfavorable outcome. CONCLUSION: PLEX may be effective in patients with ALF or ACLF. More data are needed to establish its role in the management of liver failure.http://www.ajts.org/article.asp?issn=0973-6247;year=2022;volume=16;issue=2;spage=209;epage=213;aulast=Danduacute liver failureacute on chronic liver failureliver assistive deviceplasmapheresis
spellingShingle Himanshu Dandu
Vivek Kumar
Amit Goel
Dheeraj Khetan
Tulika Chandra
Vipin Raj Bharti
A preliminary experience of plasma exchange in liver failure
Asian Journal of Transfusion Science
acute liver failure
acute on chronic liver failure
liver assistive device
plasmapheresis
title A preliminary experience of plasma exchange in liver failure
title_full A preliminary experience of plasma exchange in liver failure
title_fullStr A preliminary experience of plasma exchange in liver failure
title_full_unstemmed A preliminary experience of plasma exchange in liver failure
title_short A preliminary experience of plasma exchange in liver failure
title_sort preliminary experience of plasma exchange in liver failure
topic acute liver failure
acute on chronic liver failure
liver assistive device
plasmapheresis
url http://www.ajts.org/article.asp?issn=0973-6247;year=2022;volume=16;issue=2;spage=209;epage=213;aulast=Dandu
work_keys_str_mv AT himanshudandu apreliminaryexperienceofplasmaexchangeinliverfailure
AT vivekkumar apreliminaryexperienceofplasmaexchangeinliverfailure
AT amitgoel apreliminaryexperienceofplasmaexchangeinliverfailure
AT dheerajkhetan apreliminaryexperienceofplasmaexchangeinliverfailure
AT tulikachandra apreliminaryexperienceofplasmaexchangeinliverfailure
AT vipinrajbharti apreliminaryexperienceofplasmaexchangeinliverfailure
AT himanshudandu preliminaryexperienceofplasmaexchangeinliverfailure
AT vivekkumar preliminaryexperienceofplasmaexchangeinliverfailure
AT amitgoel preliminaryexperienceofplasmaexchangeinliverfailure
AT dheerajkhetan preliminaryexperienceofplasmaexchangeinliverfailure
AT tulikachandra preliminaryexperienceofplasmaexchangeinliverfailure
AT vipinrajbharti preliminaryexperienceofplasmaexchangeinliverfailure